AbbVie has announced plans to acquire Nimble Therapeutics in a $200 million deal. The acquisition brings Nimble’s pioneering ...
Imlunestrant, an oral SERD, significantly prolonged progression-free survival in patients with advanced ER+, HER2- breast ...
General Inception, a global biotech company igniter, has acquired Enable Medicine, a leader in Artificial Intelligence-driven ...
The DREAMM-7 trial shows belantamab mafodotin combined with bortezomib and dexamethasone significantly improves overall ...
Synaffix announces that it has entered into a licensing agreement with Elevation Oncology to develop EO-1022, a HER3-targeting Antibody-Drug Conjugate (ADC) leveraging Synaffix’s advanced platform ...
Merck has announced that the Phase 3 KEYLYNK-001 trial demonstrated that KEYTRUDA® (pembrolizumab) combined with chemotherapy ...
The AMPLIFY Phase III trial demonstrates that acalabrutinib plus venetoclax significantly improves progression-free survival ...
FDA has granted accelerated approval to Bizengri® (zenocutuzumab-zbco), a first-in-class bispecific antibody targeting NRG1+ ...
Adding Blinatumomab to Chemotherapy Extends 96% Disease-Free Survival in Pediatric Leukemia Patients
Adding BLINCYTO® (blinatumomab) to chemotherapy significantly improves three-year disease-free survival (96%) in children ...
Durvalumab (Imfinzi) has received Priority Review from the FDA for muscle-invasive bladder cancer (MIBC). Backed by positive ...
FDA has approved Durvalumab (Imfinzi) as the first and only immunotherapy for adult patients with limited-stage small cell ...
The FDA has granted Breakthrough Therapy Designation to datopotamab deruxtecan (Dato-DXd) for advanced EGFR-mutated non-small cell lung cancer.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback